At a recent Make America Healthy Again summit, US Health Secretary Robert F Kennedy Jr placed psychiatric medication overuse at the centre of a national mental health crisis. Children, he said, were especially affected. His announcement promised clear and decisive federal action. Clinicians who looked at the underlying figures reached a very different conclusion.

Government data released the year before actually undercut that overuse claim. The Assistant Secretary for Planning and Evaluation found that overall use of psychiatric medication among young people remained relatively low. No single medication class exceeded 5.3 percent of the population aged three to seventeen. That is hardly a nation drowning in prescriptions for its children.

Is Psychiatric Medication Overuse the Real Story?

Alongside the secretary’s remarks, the department issued a gentler letter to prescribers. It acknowledged that psychiatric medications can play an important, at times essential, role in treatment. For many patients, it said, these medications reduce symptoms and support recovery. That nuance sat awkwardly next to the louder message about overuse. Psychiatrists interviewed by JAMA Medical News worried the mixed signal could do more harm than good.

Several experts see the opposite problem as more urgent. Around eighteen percent of the population will experience major depressive disorder in their lifetime. Yet only about one in five of them ever receive treatment, according to psychopharmacologist Joseph Goldberg of the Mount Sinai School of Medicine. A former president of the American Psychiatric Association put it plainly. The real national conversation, she argued, should focus on undertreated illness, not on trimming prescriptions that are already comparatively modest.

Where the Overprescribing Narrative Began

The push to investigate psychiatric drug overprescribing did not appear from nowhere. An executive order signed in February set up a commission. It was tasked with assessing the risk posed by prescribing antidepressants, antipsychotics, mood stabilisers, stimulants and weight loss drugs. Instead, it proposed, public health should focus on nutrition and lifestyle change.

Members of Congress later pushed back. They asked the secretary to withdraw statements they viewed as stigmatising. Among these was a widely criticised claim that certain antidepressants are more addictive than heroin.

That comparison troubles clinicians, because it blurs a meaningful distinction. Stopping some psychiatric medications abruptly can cause withdrawal symptoms such as nausea, headache and vomiting. But withdrawal is not the same as addiction. Prescribers are clear that patients should never be encouraged to stop cold turkey. Confusing the two risks frightening people away from treatment that, for many, prevents relapse and reduces the danger of disability or suicide.

Deprescribing Safely, Not Stopping Suddenly

None of this means every prescription is appropriate forever. A consensus statement from an international panel of specialists, including Goldberg, set out guidance on deprescribing. It explains when monitored tapering is warranted and how it should be carried out gradually, under supervision. The panel even debated the word deprescribing itself. Some members worried it could be mistaken for the position of campaigners who want psychiatric medication eliminated altogether.

Roughly forty percent of people with major depressive disorder respond to first line antidepressants. That leaves considerable room for careful review of what is working and what is not. When one medication is withdrawn, clinicians say, it is usually because another approach looks more promising for that individual. It is rarely because medication itself has fallen out of favour.

Wider system pressures matter too. Between 2016 and 2019, more than sixty percent of psychotropic prescriptions came from health professionals outside psychiatry. Often these were primary care doctors managing heavy caseloads with limited specialist training in mental illness. Meanwhile, the public itself appears wary of federal interference. A survey published in January found three times as many respondents opposed restrictions on antidepressant prescribing as supported them.

The Evidence Behind Psychiatric Medication Overuse Claims

Framing every prescription as overmedicalisation oversimplifies a genuinely complicated picture, one leading psychopharmacologist warned. Some proposed alternatives, such as dietary change, still lack the evidence base that supports established psychiatric care. They may complement good care, but they cannot yet replace it. Reliable guidance on appropriate use protects patients far better than headline claims of psychiatric medication overuse that the data do not confirm.

For families, educators and communities focused on genuine prevention, the lesson is a familiar one. Accurate information beats alarming rhetoric every time. The bigger risk sits elsewhere: a substantial number of people still cannot access proper mental health support in the first place. Fixing that gap would do far more to protect the next generation than targeting prescriptions that are already comparatively rare among young people.

Source: jamanetwork